AstraZeneca promises more partnerships after Q3 results vindicate CEO’s patent deals strategy

AstraZeneca promises more partnerships after Q3 results vindicate CEO’s patent deals strategy

After revealing that patent-based deals had helped to shore up its revenues and boost core operating profits in the third quarter of 2017, AstraZeneca has said it will continue its controversial strategy of selling stakes in and offering licences to…

Unlock unlimited access to all IAM content